Boundless Bio, Inc. (BOLD) intrinsic value & 10-year financials
Boundless Bio, Inc. (BOLD) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.34
- Market cap
- $52.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -12.6%
- Free cash flow (FY2025)
- -$47.2M
BOLD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$58.2M | -$2.60 | -$47.2M | — | -42.6% |
| FY2024 | — | -$65.4M | -$3.85 | -$63.4M | — | -42.7% |
| FY2023 | — | -$49.4M | -$2.90 | -$47.5M | — | 47.4% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Boundless Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Boundless Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.6% ROIC.
Boundless Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Boundless Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.